11β-HSD1-Mediated Cortisol Signalling in Fibrosis and Impaired Diabetic Wound Healing: Current Evidence and Emerging Mechanisms
- 1Research Centre for Health, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Cowcaddens Rd, Glasgow G4 0BA, UK
- 2Leeds Teaching Hospitals NHS Trust, Trust HQ, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
- 3Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Woodhouse, Leeds LS2 9JT, UK
Abstract
Diabetic wound healing is characterised by persistent inflammation, impaired angiogenesis, extracellular matrix (ECM) dysregulation, and defective tissue remodelling, frequently resulting in chronic wounds such as diabetic foot ulcers (DFUs). Fibrosis, characterised by excessive ECM deposition and sustained fibroblast activation, is increasingly recognised as an important barrier to effective wound repair in patients with diabetes. Emerging evidence suggests that glucocorticoid signalling, particularly through the stress hormone cortisol and its activating enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), may contribute to pathological and fibrotic changes in diabetic skin by altering inflammation, extracellular matrix turnover, angiogenesis, and cellular behaviour. In parallel, connective tissue growth factor (CTGF) and insulin-like growth factor binding protein-5 (IGFBP-5) have been associated with profibrotic processes, although the evidence for their roles in diabetic wound healing is limited, particularly for IGFBP-5. This review examines current evidence regarding the role of 11β-HSD1-mediated cortisol signalling in fibrosis and impaired diabetic wound healing, with particular emphasis on its potential interactions with CTGF and IGFBP-5. However, whether and how these mediators interact with cortisol signalling in diabetic wounds remains poorly understood. Evidence from preclinical and early clinical studies suggests that inhibition of 11β-HSD1 may improve wound repair and tissue integrity; however, many existing studies rely on acute wound models and do not fully reflect the chronic inflammatory and fibrotic environment of diabetic wounds.
Related
- Pericyte-mediated intercellular crosstalk in renal fibrosis: regulatory mechanisms and intervention strategies
- Selective inhibition of IL-6 trans-signalling reveals distinct mechanisms of human classic and trans-signalling receptor-complex formation
- Enhanced glucose uptake in cardiac and skeletal muscles in Danon disease results from the impaired chaperone-mediated autophagy.
- A novel 5-HT2A receptor-linked signalling pathway involving NAADP-mediated lysosomal Ca2+ release
- Impaired regulatory T cell mediated immune tolerance promotes neurodegeneration in glaucoma
BibTeX
@article{lao202611βhsd1mediated,
title = {{11β-HSD1-Mediated Cortisol Signalling in Fibrosis and Impaired Diabetic Wound Healing: Current Evidence and Emerging Mechanisms}},
author = {Carol-Ann Lao and Begonya Alcacer-Pitarch and Steven Patterson and Ana Tiganescu and Catherine S. Wright},
journal = {Diabetology},
year = {2026},
month = oct,
doi = {10.3390/diabetology7100193},
url = {https://doi.org/10.3390/diabetology7100193},
note = {CC BY},
}
RIS
TY - JOUR
TI - 11β-HSD1-Mediated Cortisol Signalling in Fibrosis and Impaired Diabetic Wound Healing: Current Evidence and Emerging Mechanisms
AU - Carol-Ann Lao
AU - Begonya Alcacer-Pitarch
AU - Steven Patterson
AU - Ana Tiganescu
AU - Catherine S. Wright
PY - 2026
DA - 2026/10/26
JO - Diabetology
DO - 10.3390/diabetology7100193
UR - https://doi.org/10.3390/diabetology7100193
AB - Diabetic wound healing is characterised by persistent inflammation, impaired angiogenesis, extracellular matrix (ECM) dysregulation, and defective tissue remodelling, frequently resulting in chronic wounds such as diabetic foot ulcers (DFUs). Fibrosis, characterised by excessive ECM deposition and sustained fibroblast activation, is increasingly recognised as an important barrier to effective wound repair in patients with diabetes. Emerging evidence suggests that glucocorticoid signalling, particularly through the stress hormone cortisol and its activating enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), may contribute to pathological and fibrotic changes in diabetic skin by altering inflammation, extracellular matrix turnover, angiogenesis, and cellular behaviour. In parallel, connective tissue growth factor (CTGF) and insulin-like growth factor binding protein-5 (IGFBP-5) have been associated with profibrotic processes, although the evidence for their roles in diabetic wound healing is limited, particularly for IGFBP-5. This review examines current evidence regarding the role of 11β-HSD1-mediated cortisol signalling in fibrosis and impaired diabetic wound healing, with particular emphasis on its potential interactions with CTGF and IGFBP-5. However, whether and how these mediators interact with cortisol signalling in diabetic wounds remains poorly understood. Evidence from preclinical and early clinical studies suggests that inhibition of 11β-HSD1 may improve wound repair and tissue integrity; however, many existing studies rely on acute wound models and do not fully reflect the chronic inflammatory and fibrotic environment of diabetic wounds.
SN - 2673-4540
ER -